tiprankstipranks
Trending News
More News >

Maze Therapeutics initiated with an Outperform at Leerink

Leerink initiated coverage of Maze Therapeutics (MAZE) with an Outperform rating and $28 price target Maze is a clinical-stage biotechnology company focused on leveraging human genetics to develop novel, small-molecule precision medicines across renal, cardiovascular, and related metabolic diseases, the analyst tells investors in a research note. The firm says the company is developing therapies in areas of significant unmet need and strategic interest, which should resonate favorably with investors. It believes the shares can move higher over the next 12 months.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1